Actavis Inc (ACT) 232.74 $ACT
Actavis' Bystolic Combination Gets Negative FDA Panel Vote - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 3:45PM CDT
Actavis plc (ACT) announced that the FDA's CRDAC has voted against the approval (in the ratio of 6:4) of Actavis' fixed-dose combination (FDC) of Bystolic (nebivolol) and Novartis' (NVS) Diovan (valsartan).
FDA Advisory Committee Recommends Against Approval of Actavis' Nebivolol/Valsartan Fixed-Dose Combination NDA for Treatment of Hypertension
PR Newswire - Tue Sep 09, 4:10PM CDT
Actavis plc (NYSE: ACT) today confirmed that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has voted to recommend against approval of Actavis' New Drug Application (NDA) for the fixed-dose combination of nebivolol and valsartan for the treatment of hypertension. The committee vote was six to four recommending against approval.
Equity Coverage on Pharma Industry - Zoetis, Actavis, Horizon Pharma, Hospira, and Endocyte
PR Newswire - Tue Sep 09, 7:55AM CDT
On Monday, September 08, 2014, the NASDAQ Composite ended at 4,592.29, up 0.20%, the Dow Jones Industrial Average finished the day 0.15% lower at 17,111.42, and the S&P 500 closed at 2,001.54, down 0.31%. The losses were broad based with eight out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index ended the day at 741.59, up 0.05%, with the index gaining 6.75% in the previous three months. Investor-Edge has initiated coverage on the following equities: Zoetis Inc. (NYSE: ZTS), Actavis PLC (NYSE: ACT), Horizon Pharma Inc. (NASDAQ: HZNP), Hospira Inc. (NYSE: HSP), and Endocyte Inc. (NASDAQ: ECYT). Free research on these five companies can be accessed at:
Actavis' Antibiotic under FDA Review, Response in 1Q15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:20PM CDT
Actavis plc (ACT) announced the acceptance of its new drug application for its antibiotic candidate, ceftazidime-avibactam, by the FDA.
Is It Time to Buy Actavis plc Stock?
George Budwell, The Motley Fool - Motley Fool - Mon Sep 08, 1:15PM CDT
By all available metrics, the healthcare sector has been performing admirably so far this year. Despite a weak second quarter, most healthcare stocks have seen their share prices climb by double digits for a third straight year. While the sector...
Technical Updates, Upcoming Events, Awards Ceremony, and NDA Filing - Research Reports on Mead Johnson, Philip Morris, Johnson Controls, Actavis and Bristol-Myers
PR Newswire - Mon Sep 08, 7:50AM CDT
Today, Analysts Review released its research reports regarding Mead Johnson Nutrition Company (NYSE: MJN), Philip Morris International, Inc. (NYSE: PM), Johnson Controls Inc. (NYSE: JCI), Actavis plc (NYSE: ACT) and Bristol-Myers Squibb Company (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6279-100free.
IBD 50 Showing Little Distress, But Few Big Winners
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
The IBD 50 finds itself with few signs of distress, and a fair share of success stories even as the market's uptrend moderates. It's been a month since the market started climbing from its August lows, and the main indexes have slowed their ascent....
Actavis Announces FDA Acceptance of the NDA Filing for Ceftazidime-Avibactam, a Qualified Infectious Disease Product
PR Newswire - Fri Sep 05, 7:00AM CDT
Actavis plc (NYSE: ACT) today confirmed that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' application for ceftazidime-avibactam, its investigational antibiotic for the treatment of patients with Complicated Urinary Tract Infections (cUTI) and Complicated Intra-Abdominal Infections (cIAI), including those caused by multi-drug resistant Gram-negative bacterial pathogens.
Actavis' Gastrointestinal Drug Under FDA Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 3:30PM CDT
Shares of Actavis plc (ACT) were up 0.9% after the company announced that the FDA has granted priority review status to its New Drug Application (NDA) for its gastrointestinal candidate, eluxadoline.
3 Stocks Advancing The Health Care Sector
at The Street - Thu Sep 04, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
3 Reasons Actavis plc Stock Could Rise
George Budwell, The Motley Fool - Motley Fool - Tue Sep 02, 10:39AM CDT
The healthcare sector has rebounded nicely from its second-quarter woes, with a number of big names like Gilead Sciences and Celgene Corporation posting stellar gains in recent weeks. The specialty pharmaceutical company Actavis , for...
Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline
PR Newswire - Tue Sep 02, 8:20AM CDT
Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' New Drug Application (NDA) for eluxadoline, an investigational drug for the treatment of diarrhea and abdominal pain in men and women with diarrhea predominant Irritable Bowel Syndrome (IBS-D). Actavis' NDA for eluxadoline has been granted priority review status by the FDA.
3 Reasons Teva Pharmaceutical Industries Ltd. Stock Could Rise
George Budwell, The Motley Fool - Motley Fool - Mon Sep 01, 6:56PM CDT
Generic and specialty drugmakers have been experiencing a profit bonanza as former top-selling products have lost patent protect in recent years. Actavis plc , for example, has grown total revenue by a whopping 34% in the past year alone. Not...
Upcoming Conferences Schedule, Clinical Trial Data Release Schedule, Milestone Payment, and Expansion of Partnership - Research Reports on Celgene, Actavis, Regeneron, ISIS and UnitedHealth
PR Newswire - Fri Aug 29, 8:10AM CDT
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6076-100free.
UCB Files Patent Infringement Lawsuit vs. Actavis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 3:40PM CDT
Actavis has filed an ANDA with the FDA seeking marketing approval for its generic version of UCB's Neupro. In response, UCB filed a lawsuit against Actavis.
Goldman Sachs' 50 Stocks That Matter Most to Hedge Funds
at The Street - Wed Aug 27, 9:58AM CDT
This list of 50 stocks from Goldman Sachs Spreadsheet are those that appear most frequently among the top holdings of hedge funds. The portfolio beat the S&P 500 YTD gain.
Actavis to Present at Morgan Stanley Global Healthcare Conference 2014
PR Newswire - Tue Aug 26, 3:05PM CDT
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Brenton Saunders, CEO and President of Actavis, will provide an overview and update of the Company's business at the Morgan Stanley Global Healthcare Conference 2014 in New York, NY.
Supernus' Trokendi XR Faces Generic Threat from Actavis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 3:55PM CDT
Supernus Pharmaceuticals, Inc. (SUPN) has a notice from Actavis (ACT) regarding the latter's ANDA seeking approval for the generic version of Trokendi XR.
Nasdaq Leads Mixed Session; Actavis Extends Gains
at Investor's Business Daily - Fri Aug 22, 12:27PM CDT
The Nasdaq led a quiet session in early afternoon trade Friday as major averages were unfazed by comments from Fed chief Janet Yellen in Jackson Hole, Wyo., about interest rate policy and the state of the job market. The Nasdaq rose 0.3%, while the...
Actavis Up on Positive Phase III Ceftazidime-Avibactam Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 3:30PM CDT
Actavis plc's (ACT) shares were up 2.3% with the company announcing positive top-line results from the phase III RECLAIM-1 and -2 studies on ceftazidime-avibactam.
Actavis' Bystolic Combination Gets Negative FDA Panel Vote - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 3:45PM CDT
Actavis plc (ACT) announced that the FDA's CRDAC has voted against the approval (in the ratio of 6:4) of Actavis' fixed-dose combination (FDC) of Bystolic (nebivolol) and Novartis' (NVS) Diovan (valsartan).
FDA Advisory Committee Recommends Against Approval of Actavis' Nebivolol/Valsartan Fixed-Dose Combination NDA for Treatment of Hypertension
PR Newswire - Tue Sep 09, 4:10PM CDT
Actavis plc (NYSE: ACT) today confirmed that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has voted to recommend against approval of Actavis' New Drug Application (NDA) for the fixed-dose combination of nebivolol and valsartan for the treatment of hypertension. The committee vote was six to four recommending against approval.
Equity Coverage on Pharma Industry - Zoetis, Actavis, Horizon Pharma, Hospira, and Endocyte
PR Newswire - Tue Sep 09, 7:55AM CDT
On Monday, September 08, 2014, the NASDAQ Composite ended at 4,592.29, up 0.20%, the Dow Jones Industrial Average finished the day 0.15% lower at 17,111.42, and the S&P 500 closed at 2,001.54, down 0.31%. The losses were broad based with eight out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index ended the day at 741.59, up 0.05%, with the index gaining 6.75% in the previous three months. Investor-Edge has initiated coverage on the following equities: Zoetis Inc. (NYSE: ZTS), Actavis PLC (NYSE: ACT), Horizon Pharma Inc. (NASDAQ: HZNP), Hospira Inc. (NYSE: HSP), and Endocyte Inc. (NASDAQ: ECYT). Free research on these five companies can be accessed at:
Actavis' Antibiotic under FDA Review, Response in 1Q15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:20PM CDT
Actavis plc (ACT) announced the acceptance of its new drug application for its antibiotic candidate, ceftazidime-avibactam, by the FDA.
Is It Time to Buy Actavis plc Stock?
George Budwell, The Motley Fool - Motley Fool - Mon Sep 08, 1:15PM CDT
By all available metrics, the healthcare sector has been performing admirably so far this year. Despite a weak second quarter, most healthcare stocks have seen their share prices climb by double digits for a third straight year. While the sector...
Technical Updates, Upcoming Events, Awards Ceremony, and NDA Filing - Research Reports on Mead Johnson, Philip Morris, Johnson Controls, Actavis and Bristol-Myers
PR Newswire - Mon Sep 08, 7:50AM CDT
Today, Analysts Review released its research reports regarding Mead Johnson Nutrition Company (NYSE: MJN), Philip Morris International, Inc. (NYSE: PM), Johnson Controls Inc. (NYSE: JCI), Actavis plc (NYSE: ACT) and Bristol-Myers Squibb Company (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6279-100free.
IBD 50 Showing Little Distress, But Few Big Winners
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
The IBD 50 finds itself with few signs of distress, and a fair share of success stories even as the market's uptrend moderates. It's been a month since the market started climbing from its August lows, and the main indexes have slowed their ascent....
Actavis Announces FDA Acceptance of the NDA Filing for Ceftazidime-Avibactam, a Qualified Infectious Disease Product
PR Newswire - Fri Sep 05, 7:00AM CDT
Actavis plc (NYSE: ACT) today confirmed that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' application for ceftazidime-avibactam, its investigational antibiotic for the treatment of patients with Complicated Urinary Tract Infections (cUTI) and Complicated Intra-Abdominal Infections (cIAI), including those caused by multi-drug resistant Gram-negative bacterial pathogens.
Actavis' Gastrointestinal Drug Under FDA Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 3:30PM CDT
Shares of Actavis plc (ACT) were up 0.9% after the company announced that the FDA has granted priority review status to its New Drug Application (NDA) for its gastrointestinal candidate, eluxadoline.
3 Stocks Advancing The Health Care Sector
at The Street - Thu Sep 04, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
3 Reasons Actavis plc Stock Could Rise
George Budwell, The Motley Fool - Motley Fool - Tue Sep 02, 10:39AM CDT
The healthcare sector has rebounded nicely from its second-quarter woes, with a number of big names like Gilead Sciences and Celgene Corporation posting stellar gains in recent weeks. The specialty pharmaceutical company Actavis , for...
Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline
PR Newswire - Tue Sep 02, 8:20AM CDT
Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' New Drug Application (NDA) for eluxadoline, an investigational drug for the treatment of diarrhea and abdominal pain in men and women with diarrhea predominant Irritable Bowel Syndrome (IBS-D). Actavis' NDA for eluxadoline has been granted priority review status by the FDA.
3 Reasons Teva Pharmaceutical Industries Ltd. Stock Could Rise
George Budwell, The Motley Fool - Motley Fool - Mon Sep 01, 6:56PM CDT
Generic and specialty drugmakers have been experiencing a profit bonanza as former top-selling products have lost patent protect in recent years. Actavis plc , for example, has grown total revenue by a whopping 34% in the past year alone. Not...
Upcoming Conferences Schedule, Clinical Trial Data Release Schedule, Milestone Payment, and Expansion of Partnership - Research Reports on Celgene, Actavis, Regeneron, ISIS and UnitedHealth
PR Newswire - Fri Aug 29, 8:10AM CDT
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6076-100free.
UCB Files Patent Infringement Lawsuit vs. Actavis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 3:40PM CDT
Actavis has filed an ANDA with the FDA seeking marketing approval for its generic version of UCB's Neupro. In response, UCB filed a lawsuit against Actavis.
Goldman Sachs' 50 Stocks That Matter Most to Hedge Funds
at The Street - Wed Aug 27, 9:58AM CDT
This list of 50 stocks from Goldman Sachs Spreadsheet are those that appear most frequently among the top holdings of hedge funds. The portfolio beat the S&P 500 YTD gain.
Actavis to Present at Morgan Stanley Global Healthcare Conference 2014
PR Newswire - Tue Aug 26, 3:05PM CDT
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Brenton Saunders, CEO and President of Actavis, will provide an overview and update of the Company's business at the Morgan Stanley Global Healthcare Conference 2014 in New York, NY.
Supernus' Trokendi XR Faces Generic Threat from Actavis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 3:55PM CDT
Supernus Pharmaceuticals, Inc. (SUPN) has a notice from Actavis (ACT) regarding the latter's ANDA seeking approval for the generic version of Trokendi XR.
Nasdaq Leads Mixed Session; Actavis Extends Gains
at Investor's Business Daily - Fri Aug 22, 12:27PM CDT
The Nasdaq led a quiet session in early afternoon trade Friday as major averages were unfazed by comments from Fed chief Janet Yellen in Jackson Hole, Wyo., about interest rate policy and the state of the job market. The Nasdaq rose 0.3%, while the...
Actavis Up on Positive Phase III Ceftazidime-Avibactam Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 3:30PM CDT
Actavis plc's (ACT) shares were up 2.3% with the company announcing positive top-line results from the phase III RECLAIM-1 and -2 studies on ceftazidime-avibactam.
